The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

NCT02962388 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

13

Enrollment

OTHER

Sponsor class

Stopped not enough recruitment

Conditions

Essential Thrombocythemia

Interventions

DRUG: Anagrelide
DRUG: Ruxolitinib (JAKAVI®)
DRUG: IFNα/ PegIFNα

Sponsor

French Innovative Leukemia Organisation

Collaborators

[object Object]